DTL
AVBP icon

Dynamic Technology Lab’s ArriVent BioPharma AVBP Stock Holding History

Dynamic Technology Lab’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,379
Closed -$266K – 1403
2025
Q1 		$266K Buy
+14,379
New +$352K 0.04% 744

Other funds holding AVBP

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
GCGM
General Catalyst Group Management Cambridge, Massachusetts $184M AUM 50.45% 1-Year Est. Return

Dynamic Technology Lab's AVBP Position: Q2 2025 in Review

Dynamic Technology Lab sold out of ArriVent BioPharma (AVBP) in Q2 2025, closing a stake of 14,379 shares — an estimated $266K sold.

Dynamic Technology Lab first reported a position in AVBP in Q1 2025 and held it in 1 quarter. The position peaked at $266K in Q1 2025. 99 funds tracked by Wall St. Rank hold AVBP as of Q2 2025.

  • Dynamic Technology Lab reported no remaining ArriVent BioPharma position as of Q2 2025 after selling out during the quarter.
  • Dynamic Technology Lab sold 14,379 ArriVent BioPharma shares in Q2 2025, an estimated $266K.
  • Dynamic Technology Lab first reported a position in ArriVent BioPharma in Q1 2025 and held it in 1 quarter.
  • Dynamic Technology Lab's ArriVent BioPharma position peaked at $266K in Q1 2025.
  • 99 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2025.

Based on Dynamic Technology Lab's 13F filing for Q2 2025, filed 12 Aug 2025.